proxyvotesnow.com

Home › Companies › EyePoint Pharmaceuticals, Inc. › 2024-2025

EyePoint Pharmaceuticals, Inc. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and EyePoint Pharmaceuticals, Inc.’s Form 8-K, filed 2025-06-20 (Item 5.07 on EDGAR). Page generated 02 October 2026.

  • 15Reported items
  • 179Asset managers
  • 2,193Fund votes
  • 2025-06-18Meeting date

Proxy season: 2023-2024 2024-2025

Explore EyePoint Pharmaceuticals, Inc. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by EyePoint Pharmaceuticals, Inc.

These tallies are EyePoint Pharmaceuticals, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-06-20 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

EyePoint Pharmaceuticals, Inc. — official shareholder meeting results, meeting held 2025-06-18
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Proposal 2: . Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 2,900,000 shares. The voting on this proposal is set for 41,319,55713,015,428449,689 ---- Majority: yes
Proposal 3: . Non-Binding Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement. The voting on 50,767,7103,552,037464,927 ---- Majority: yes
Proposal 5: . Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending De 60,529,812118,502184,193 ---- Majority: yes

Source: EyePoint Pharmaceuticals, Inc., Form 8-K, filed with the SEC on 2025-06-20 — read the filing on EDGAR.

How asset managers voted at the EyePoint Pharmaceuticals, Inc. 2024-2025 meeting

Each item below shows how the 179 asset managers that disclosed a EyePoint Pharmaceuticals, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of EyePoint Pharmaceuticals, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the accompanying proxy statement.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 9 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 50,767,710AGAINST: 3,552,037

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Proposal 3: . Non-Binding Advisory Vote on Named Executive Officer Compensation The Company's stockholders approved, on a non-binding advisory basis, the compensation of the Company's named executive officers as disclose”): 50,767,710 for, 3,552,037 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,811,357 outstanding shares: 74% for, 5% against (79% of the company cast a for/against vote).

The 179 asset managers below cast 93% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 93%
FOR: 93.4%AGAINST: 6.6%ABSTAIN: 0.0%NOT VOTED: 0.0%
Largest asset managers voting on “To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes9,203,13126,784 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.6,311,1180 00For
SUVRETTA CAPITAL MANAGEMENT, LLC5,946,3220 00For
FRANKLIN ADVISERS INC4,131,8810 00For
BlackRock4,010,853563 00For
Vanguard3,960,0140 00For
TCG Crossover Management, LLC3,572,3350 00For
RA CAPITAL MANAGEMENT, L.P.3,181,8180 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity2,187,4920 00For
Cormorant Asset Management, LP1,875,6190 00For
GEODE CAPITAL MANAGEMENT, LLC1,602,1160 00For
Patient Square Capital LP1,481,9770 00For
Aberdeen01,477,068 00Against
State Street1,472,1010 00For
5AM Venture Management, LLC1,050,0000 00For
Northern Trust815,0110 00For
Citadel809,0220 00For
Blue Owl Capital Holdings LP797,5940 00For
Goldman Sachs647,8120 00For
HSBC0601,319 00Against
Nantahala Capital Management, LLC593,0910 00For
Charles Schwab0393,678 00Against
Alyeska Investment Group, L.P.351,3480 00For
Artia Global Partners LP306,6990 00For

Showing the 25 largest of 179 asset managers. See all 179 in the interactive database.

2. To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our named executive officers.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

99.9% fund support · no official result

11%ONE YEAR 56%1 YEAR 34%

The 168 asset managers below cast 99.9% of the shares they voted on this item FOR (5,934,884 for, 394 against).

FOR: 5,934,884 (10.6%)AGAINST: 394 (0.0%)ABSTAIN: 6,929 (0.0%)ONE YEAR: 31,236,018 (55.7%)1 YEAR: 18,848,367 (33.6%)THREE YEARS: 12,738 (0.0%)3 YEARS: 1,831 (0.0%)NOT VOTED: 71 (0.0%)1-YEAR: 25 (0.0%)
Largest asset managers voting on “To vote, on an advisory basis, on the frequency of advisory stockholder votes on the compensation paid to our ” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes00 001 Year
SUVRETTA CAPITAL MANAGEMENT, LLC00 00One Year
FRANKLIN ADVISERS INC00 00One Year
BlackRock00 001 Year
Vanguard00 00One Year
TCG Crossover Management, LLC3,572,3350 00For
RA CAPITAL MANAGEMENT, L.P.00 00One Year
FRANKLIN STRATEGIC SERIES00 00One Year
Fidelity00 00One Year
Cormorant Asset Management, LP00 001 Year
GEODE CAPITAL MANAGEMENT, LLC00 00One Year
Patient Square Capital LP1,481,9770 00For
Aberdeen00 00One Year
State Street00 00One Year
5AM Venture Management, LLC00 001 Year
Northern Trust00 001 Year
Citadel00 00One Year
Blue Owl Capital Holdings LP797,5940 00For
Goldman Sachs00 001 Year
HSBC00 00One Year
Charles Schwab00 001 Year
Alyeska Investment Group, L.P.00 00One Year
Artia Global Partners LP00 00One Year
Woodline Partners LP00 00One Year
AXA INVESTMENT MANAGERS UK Ltd00 00One Year

Showing the 25 largest of 168 asset managers. See all 168 in the interactive database.

3. To approve Amendment No. 2 to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the number of shares of common stock authorized for issuance thereunder by 2,900,000 shares.

COMPENSATIONMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

76% Majority: yes · of votes cast

FOR 76%AGAINST 24%
FOR: 41,319,557AGAINST: 13,015,428

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Proposal 2: . Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to increase the number of shares of Common Stock authorized for issuance thereunder by 2,900,000 shares”): 41,319,557 for, 13,015,428 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,811,357 outstanding shares: 60% for, 19% against (79% of the company cast a for/against vote).

The 47 asset managers below cast 88% of the shares they voted on this item FOR (15,741,242 for, 2,072,848 against).

FOR 88%12%
FOR: 15,741,242 (88.3%)AGAINST: 2,072,848 (11.6%)ABSTAIN: 6,929 (0.0%)
Largest asset managers voting on “To approve Amendment No. 2 to the EyePoint Pharmaceuticals, Inc. 2023 Long-Term Incentive Plan to increase the” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,446,645368,000 00For
BlackRock1,492,6510 00For
Patient Square Capital LP1,481,9770 00For
Aberdeen0738,534 00Against
Northern Trust0329,819 00Against
Charles Schwab196,8370 00For
Equitable116,37558,590 00For
State Street252138,320 00Against
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial088,128 00Against
Simplify Exchange Traded Funds87,2410 00For
DWS070,116 00Against
American Century051,223 00Against
Global X38,9960 00For
AIG/SunAmerica037,477 00Against
Brighthouse023,992 6,9290Against
Pacific Life29,3960 00For
ProShares027,638 00Against
1290 Funds027,470 00Against
John Hancock022,977 00Against
T. Rowe Price022,917 00Against

Showing the 25 largest of 47 asset managers. See all 47 in the interactive database.

4. TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

Combines 2 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 60,529,812AGAINST: 118,502

EyePoint Pharmaceuticals, Inc.’s own tally for this item (“Proposal 5: . Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the Company's independent registered public accou”): 60,529,812 for, 118,502 against, per its Form 8-K filed 2025-06-20 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 68,811,357 outstanding shares: 88% for, 0.2% against (88% of the company cast a for/against vote).

The 46 asset managers below cast 99.9% of the shares they voted on this item FOR (17,813,745 for, 306 against).

FOR 99.9%
FOR: 17,813,745 (100.0%)AGAINST: 306 (0.0%)ABSTAIN: 6,929 (0.0%)
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF DELOITTE & TOUCHE LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING F” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Patient Square Capital LP1,481,9770 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,54824 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
Simplify Exchange Traded Funds87,2410 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

5. Election of Directors: Fred Hassan

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,244,833 for, 0 against).

FOR: 16,244,833 (100.0%)ABSTAIN: 6,929 (0.0%)
Largest asset managers voting on “Election of Directors: Fred Hassan” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,5720 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

6. Election of Directors: Goran Ando, M.D.

DIRECTOR ELECTIONS

Combines 6 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (17,530,100 for, 0 against).

FOR: 17,530,100 (98.9%)ABSTAIN: 202,822 (1.1%)
Largest asset managers voting on “Election of Directors: Goran Ando, M.D.” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Patient Square Capital LP1,481,9770 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street4730 138,0990Abstain
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial40,9280 47,2000Abstain
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

7. Election of Directors: Jay S. Duker, M.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,244,833 for, 0 against).

FOR: 16,244,833 (100.0%)ABSTAIN: 6,929 (0.0%)
Largest asset managers voting on “Election of Directors: Jay S. Duker, M.D.” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,5720 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

8. Election of Directors: John B. Landis, Ph.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,056,060 for, 0 against).

FOR: 16,056,060 (98.8%)ABSTAIN: 195,702 (1.2%)
Largest asset managers voting on “Election of Directors: John B. Landis, Ph.D.” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street4730 138,0990Abstain
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial40,9280 47,2000Abstain
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

9. Election of Directors: Karen Zaderej

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,244,551 for, 0 against).

FOR: 16,244,551 (100.0%)ABSTAIN: 7,211 (0.0%)
Largest asset managers voting on “Election of Directors: Karen Zaderej” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,5720 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

10. Election of Directors: Nancy Lurker

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,056,060 for, 0 against).

FOR: 16,056,060 (98.8%)ABSTAIN: 195,702 (1.2%)
Largest asset managers voting on “Election of Directors: Nancy Lurker” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street4730 138,0990Abstain
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial40,9280 47,2000Abstain
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

11. Election of Directors: Reginald Sanders, M.D.

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,244,833 for, 0 against).

FOR: 16,244,833 (100.0%)ABSTAIN: 6,929 (0.0%)
Largest asset managers voting on “Election of Directors: Reginald Sanders, M.D.” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,5720 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

12. Election of Directors: Stuart Duty

DIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,244,551 for, 0 against).

FOR: 16,244,551 (100.0%)ABSTAIN: 7,211 (0.0%)
Largest asset managers voting on “Election of Directors: Stuart Duty” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,5720 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

13. Election of Directors: Wendy DiCicco

DIRECTOR ELECTIONS

Combines 4 wordings of this item as funds reported it.

100% fund support · no official result

FOR 99.9%

The 44 asset managers below cast 100% of the shares they voted on this item FOR (16,244,551 for, 0 against).

FOR: 16,244,551 (100.0%)ABSTAIN: 7,211 (0.0%)
Largest asset managers voting on “Election of Directors: Wendy DiCicco” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Federated Hermes4,588,9240 00For
Vanguard3,783,7800 00For
FRANKLIN STRATEGIC SERIES2,207,1680 00For
Fidelity1,814,6450 00For
BlackRock1,492,6510 00For
Aberdeen738,5340 00For
Northern Trust329,8190 00For
Charles Schwab196,8370 00For
Equitable174,9650 00For
State Street138,5720 00For
TIAA121,8120 00For
QUANTITATIVE MASTER SERIES LLC112,6190 00For
Lincoln Financial88,1280 00For
DWS70,1160 00For
American Century51,2230 00For
Global X38,9960 00For
AIG/SunAmerica37,4770 00For
Brighthouse23,9920 6,9290For
Pacific Life29,3960 00For
ProShares27,6380 00For
1290 Funds27,4700 00For
John Hancock22,9770 00For
T. Rowe Price22,9170 00For
Bridge Builder Trust21,9260 00For
ETFis Series Trust I18,0770 00For

Showing the 25 largest of 44 asset managers. See all 44 in the interactive database.

14. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

1-YEAR 99%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

1-YEAR: 6,311,118 (98.7%)ONE YEAR: 84,614 (1.3%)1 YEAR: 1,738 (0.0%)
Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.00 001-Year
ESSEX INVESTMENT MANAGEMENT CO LLC00 00One Year
JPMorgan00 00One Year
Granahan Investment Management, LLC00 001 Year

15. 14A Executive Compensation Vote Frequency

SECTION 14A SAY-ON-PAY VOTES

100% fund support · no official result

FOR 99.4%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (87,241 for, 0 against).

FOR: 87,241 (99.4%)1 YEAR: 500 (0.6%)
Largest asset managers voting on “14A Executive Compensation Vote Frequency” at EyePoint Pharmaceuticals, Inc., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Simplify Exchange Traded Funds87,2410 00For
Focus Partners Wealth00 001 Year

Largest EyePoint Pharmaceuticals, Inc. shareholders voting in 2024-2025

Ranked by the number of EyePoint Pharmaceuticals, Inc. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 68,811,357 shares outstanding at the time of that meeting.

Top EyePoint Pharmaceuticals, Inc. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Federated Hermes 13.41%
2ADAGE CAPITAL PARTNERS GP, L.L.C. 9.17%
3SUVRETTA CAPITAL MANAGEMENT, LLC 8.64%
4FRANKLIN ADVISERS INC 6.00%
5BlackRock 5.83%
6Vanguard 5.75%
7TCG Crossover Management, LLC 5.19%
8RA CAPITAL MANAGEMENT, L.P. 4.62%
9FRANKLIN STRATEGIC SERIES 3.21%
10Fidelity 3.18%

Reported EyePoint Pharmaceuticals, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

EyePoint Pharmaceuticals, Inc. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Cormorant Asset Management, LP 12.01% 13G
BlackRock 8.32% 13F
Suvretta Capital Management 6.94% DEF14A
Federated Hermes, Inc. 6.68% 13G
Commodore Capital LP 6.18% 13G
Franklin Templeton 6.03% 13F
Franklin Resources, Inc. 6.01% DEF14A
Vanguard Group 5.57% 13F
TCG Crossover GP II, LLC 5.19% 13G
Adage Capital Management, L.P. 4.80% 13G

Percentages above are of 68,811,357 shares outstanding, as reported by EyePoint Pharmaceuticals, Inc. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from EyePoint Pharmaceuticals, Inc.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At EyePoint Pharmaceuticals, Inc.'s shareholder meeting held 2025-06-18, in the 2024-2025 proxy season, 179 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,193 separate fund positions. Their filings are grouped here into 15 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation paid to the Company's named executive… — FOR was 93% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: EyePoint Pharmaceuticals, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-06-20.

EyePoint Pharmaceuticals, Inc. proxy season coverage: 2023-2024 · 2024-2025 (this page).